

A Publication of Central Oklahoma Classic Chevy Club January 2021

JANUARY MEETING. January club meeting will be held January 10 at 3 PM at the Johnnie's in Edmond, 33 East 33rd. Their community room is extra large and provides for social distancing for the attendees.

CENTRAL OKLAHOMA CLASSIC CHEVY CLUB—Minutes

President Dale Kosa called the November 8, 2020 meeting to order at 3:00 pm at Johnnie's in Edmond. Joe McIninch: birthday. Rodney and Martha Duerksen had an anniversary, 40 yrs.

Minutes from the Oct meeting printed in the DashBoard. Motion was made and seconded that we accept them as corrected - for date of Christmas party is the 12th of Dec. Motion passed.

Treasurer's report was read by Adeline Yerkes in absence of Teresa Linn, Treas. **NEW BUSINESS:** Club calendars, 80 printed. Recommend each family gets one free calendar. Would pay \$5.00 for each additional. Rodney made motion that each additional calendar would cost \$5.00. Discussion. Rodney withdrew motion. Joe made motion, Donna seconded "calendars be distributed to members present and roster kept for those distributed, pay \$5.00 for each additional." Motion passed. Motion by Mike, Bob Donaldson's work on the calendars should be reimbursed. Motion tabled until next meeting.

CHRISTMAS PARTY: Joe and Donna will host party Dec 12, 1:00pm. \$15 gift man or women. Meat is being provided by specific members and others bring side dishes. Some CHEVY EMBLEMS will need to be worn or driven to future meetings Enforcement will start.

LADIES CHOICE went to Rodney Duerksen

Fall Foliage trip: for those who could not go. About 9 people traveled on Fri. had lunch in Claremore. Total attendance 48 people. Had good tree colors. Visited Rt 66 Museum. Next years Fall Foliage is Tulsa's turn. Terry and Kay Simpson are in charge. No location yet.

PROGRESS REPORT on Linda Mertens by Gary. She is getting her last treatment and her hair is coming back.

MOTION to adjourn 4:00pm

Submitted by Secretary Martha Duerksen

Central Oklahoma Classic Car Club Officers

President: Dale Kosa Secretary: Martha Duerksen

1st Vice President: Mike Yerkes Treasurer: Teresa Linn

2nd Vice-Presidents: Rustyne Harris and Adeline Yerkes





I pledge allegiance to the flag of the United States of America, and to the republic for which it stands, one nation, under God, indivisible with liberty and justice for all.

Central OK Classic Chevy Club Adeline Yerkes, Editor

https://www.55-57chevys.com/

Information Related to obtaining COVID 19 Immunization

If you live in Oklahoma County – this is the website for the Health Department

OKC-County Health Department: COVID Vaccine (occhd.org)

To sign up for an appointment you must register on-line and us Facebook, or some other form of social media

(1) OKC-County Health Department | Facebook

OCCHD: Vaccination Clinic for 65+ (signupgenius.com)

All appointments are taken for the January 7th clinic

If you live in Logan County – this is the website information

Sign up for the immunization -

Over 65/Healthcare/First Responders: Guthrie January 7th, 2021 Vaccination POD (signupgenius.com)

All appointment are taken for January 7th clinic

If you live in Cleveland County – this is the website information

(1) Cleveland County Health Department | Facebook

I have attached the Consent form and the Registration form for your use.



If you answer "yes" to any question, it does not necessarily



For vaccine recipients:	Patient Name	
TOT Vaccifie recipients.		
The following questions will help us determine if there is	Amo	
any reason you should not get the COVID-19 vaccine today.	Age	

mean you should not be vaccinated. It just means additional questions may be asked. If a question is not clear, please ask your healthcare provider to explain it. Don't Yes know 1. Are you feeling sick today? **2.** Have you ever received a dose of COVID-19 vaccine? • If yes, which vaccine product? Pfizer ☐ Moderna Another product **3.** Have you ever had a severe allergic reaction (e.g., anaphylaxis) to something? For example, a reaction for which you were treated with epinephrine or EpiPen®, or for which you had to go to the hospital? Was the severe allergic reaction after receiving a COVID-19 vaccine? • Was the severe allergic reaction after receiving another vaccine or another injectable medication? 4. Have you received passive antibody therapy (monoclonal antibodies or convalescent serum) as treatment for COVID-19? **5.** Have you received another vaccine in the last 14 days? 6. Have you had a positive test for COVID-19 or has a doctor ever told you that you had COVID-19? 7. Do you have a weakened immune system caused by something such as HIV infection or cancer or do you take immunosuppressive drugs or therapies? **8.** Do you have a bleeding disorder or are you taking a blood thinner? **9.** Are you pregnant or breastfeeding?

Form reviewed by

Date



Information for Healthcare Professionals



For additional information on COVID-19 vaccine clinical guidance, see: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html.

For additional information on ACIP general recommendations, see: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html.

Two COVID-19 vaccines are currently authorized for use in the United States. These vaccines are authorized for use among different age populations.

PRODUCT	AUTHORIZED AGE GROUPS
Pfizer-BioNTech COVID-19 Vaccine	16 years of age and older
Moderna COVID-19 Vaccine	18 years of age and older

Anyone outside of the authorized age groups for a product should not receive the vaccine.

Are you feeling sick today?

There is no evidence that acute illness reduces vaccine efficacy or increases vaccine adverse events. However, as a precaution with moderate or severe acute illness, all vaccines should be delayed until the illness has improved. **Mild illnesses (e.g., upper respiratory infections, diarrhea) are NOT contraindications to vaccination.** Do not withhold vaccination if a person is taking antibiotics.

Vaccination of persons with current SARS-CoV-2 infection should be deferred until the person has recovered from acute illness and they can discontinue isolation. This recommendation applies to persons who develop SARS-CoV-2 infection before receiving any vaccine doses as well as those who develop SARS-CoV-2 infection after the first dose but before receipt of the second dose.

Have you ever received a dose of COVID-19 vaccine?

COVID-19 vaccines are **NOT** interchangeable. Currently authorized COVID-19 vaccines require two doses. Both doses of the series should be completed with the same product. Product dosing schedules vary.

Check medical records, immunization information systems, and vaccination record cards to help determine the initial product received. Those who received a trial vaccine should consult with the trial sponsors to determine if it is feasible to receive additional doses.

PRODUCT	DOSING SCHEDULE Between doses 1 and 2
Pfizer-BioNTech COVID-19 Vaccine	21 days
Moderna COVID-19 Vaccine	28 days

The second dose should be administered as close to the recommended interval as possible. The vaccine can be given up to four days in advance of the recommended interval if a patient presents early and you are concerned they will not return at the appropriate interval for vaccination. However, there is no maximum interval between the first and second dose for either vaccine. The series does not need to be restarted.

12/21/20 CS321629-E 3



Information for Healthcare Professionals



COVID-19 Vaccine Components

Description	Pfizer-BioNTech COVID-19 vaccine	Moderna COVID-19 vaccine
mRNA	Nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2	Nucleoside-modified mRNA encoding the viral spike (S) glycoprotein of SARS-CoV-2
	2[(polyethylene glycol)-2000]-N, N-ditetradecylacetamide	Polyethylene glycol (PEG) 2000 dimyristoyl glycerol (DMG)
Limida	1,2-distearoyl-sn-glycero-3-phosphocholine	1,2-distearoyl-sn-glycero-3-phosphocholine
Lipids	Cholesterol	Cholesterol
	(4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl) bis(2-hexyldecanoate)	SM-102 (Proprietary to Moderna)
	Potassium chloride	Tromethamine
Calta	Monobasic potassium phosphate	Tromethamine hydrochloride
Salts, sugars, buffers	Sodium chloride	Acetic acid
bullers	Dibasic sodium phosphate dihydrate	Sodium acetate
	Sucrose	Sucrose

Have you ever had a severe allergic reaction (e.g., anaphylaxis) to something? For example, a reaction for which you were treated with epinephrine or EpiPen®, or for which you had to go to the hospital?

Allergic reactions, including severe allergic reactions, NOT related to vaccines or injectable therapies (e.g., food, pet, venom, environmental, or latex allergies; oral medications) are NOT a contraindication or precaution to vaccination with currently authorized COVID-19 vaccine. HOWEVER, individuals who have had severe allergic reactions to something, regardless of cause, **should be observed for 30 minutes after vaccination.** All other persons should be observed for 15 minutes.

Was the severe allergic reaction after receiving a COVID-19 vaccine?

History of severe allergic reaction (e.g., anaphylaxis) to a previous dose or component of the COVID-19 vaccine product being offered is a contraindication to any current COVID-19 vaccine. Ask questions about previous severe reactions that might indicate an allergy to a vaccine component. For example, PEG may have been a component of medication for a colonoscopy.

Was the severe allergic reaction after receiving another vaccine or another injectable medication?

History of severe allergic reaction (e.g., anaphylaxis) to another vaccine or a component of another vaccine OR anaphylactic reaction to any other injectable medication is a **precaution to currently authorized COVID-19 vaccine.** Vaccine may be given, but counsel patients about unknown risks of developing a severe allergic reaction and balance these risks against the benefits of vaccination. These individuals should be observed for 30 minutes after vaccination. A history of mild allergic reaction to a vaccine or injectable therapy is not a precaution to vaccination.

Healthcare professionals should be familiar with identifying immediate-type allergic reactions, including anaphylaxis, and be competent in treating these events at the time of vaccine administration. Appropriate medical treatment for severe allergic reactions must be immediately available in the event that an acute anaphylactic reaction occurs following administration of a COVID-19 vaccine.

See Management of Anaphylaxis at COVID-19 Vaccination Sites | CDC for additional guidance.

Have you received passive antibody therapy as treatment for COVID-19?

Based on the estimated half-life of monoclonal antibodies or convalescent plasma as part of COVID-19 treatment, as well as evidence suggesting that reinfection is uncommon in the 90 days after initial infection, **vaccination should be deferred for at least 90 days**, as a precautionary measure until additional information becomes available, to avoid interference of the antibody treatment with vaccine-induced immune responses.

12/21/20 CS321629-E



Information for Healthcare Professionals



Clinical Consideration Questions

Responses to these questions are not (on their own) contraindications or precautions to vaccination. However, healthcare professionals should be prepared to discuss information and options with patients based on their responses to the following questions.

Have you received another vaccine in the last 14 days?

COVID-19 vaccine series should be administered alone, with a minimum interval of 14 days before or after administration with other vaccines. This recommendation is based on the lack of data on the safety and efficacy of mRNA COVID-19 vaccines administered simultaneously with other vaccines.

Have you had a positive test for COVID-19 or has a doctor ever told you that you had COVID-19?

Vaccination should be offered to persons regardless of history of prior symptomatic or asymptomatic SARS-CoV-2 infection. Vaccination of persons with known current SARS-CoV-2 infection should be deferred until the person has recovered from the acute illness (if the person had symptoms) and criteria have been met for them to discontinue isolation.

Persons with documented acute SARS-CoV-2 infection in the preceding 90 days may delay vaccination until near the end of this period, if desired, because current evidence suggests reinfection is uncommon during this time.

Viral testing to assess for acute SARS-CoV-2 infection or serologic testing to assess for prior infection solely for the purposes of vaccine decision-making is not recommended.

Do you have a weakened immune system caused by something such as HIV infection or cancer or do you take immunosuppressive drugs or therapies?

Persons with HIV infection or other immunocompromising conditions, or who take immunosuppressive medications or therapies might be at increased risk for severe COVID-19. mRNA COVID-19 vaccines may be administered to persons with underlying medical conditions who have no contraindications to vaccination. However, they should be counseled about the unknown vaccine safety profile and effectiveness in immunocompromised populations, as well as the potential for reduced immune responses and the need to continue to follow all current guidance to protect themselves against COVID-19, including wearing a mask, social distancing, and washing hands frequently.

Do you have a bleeding disorder or are you taking a blood thinner?

COVID-19 vaccine may be given to these patients, if a physician familiar with the patient's bleeding risk determines that the vaccine can be administered intramuscularly with reasonable safety. ACIP recommends the following technique for intramuscular vaccination in patients with bleeding disorders or taking blood thinners: a fine-gauge needle (23-gauge or smaller caliber) should be used for the vaccination, followed by firm pressure on the site, without rubbing, for at least 2 minutes.

Are you pregnant or breastfeeding?

If pregnant people are part of a group that is recommended to receive a COVID-19 vaccine (e.g., healthcare personnel), they may choose to be vaccinated. For pregnant people seeking guidance in making a decision, pregnant people and their healthcare providers should consider the level of COVID-19 community transmission, the patient's personal risk of contracting COVID-19, the risks of COVID-19 to the patient and potential risks to the fetus, the efficacy of the vaccine, the side effects of the vaccine, and the lack of data about the vaccine during pregnancy.

A lactating person who is part of a group recommended to receive a COVID-19 vaccine (e.g., healthcare personnel) may choose to be vaccinated. There are no data on the safety of COVID-19 vaccines in lactating people or the effects of mRNA COVID-19 vaccines on the breastfed infant or milk production/excretion.

12/21/20 CS321629-E

CLIENT INFORMATION	NC								1000 00-00	
Name (Last, First, MI)					Suffix (eg., Jr, III)		Date of Bi	rth		Age†
Street Address		· · · · · · · · · · · · · · · · · · ·		City	1	State	Zip		County	,
Phone Number	□ Cell □ Home	Sex ☐ Female ☐ Male ☐ Other ☐ Unknown	Race ☐ American Indian		Native ☐ Asian ☐ BI Pacific Islander ☐ Whi				i ty: □ Hispani Hispanic/Latino	
	to client: D Father	se complete guardian inform Mother Legal Guard		dian Na	ame (Last, First)		200	·		
I, the undersigned, giv the risks and bene the information re management, and	re my consent for t efits for these servi garding myself and I billing purposes.	he services that I am reque- ces will be explained to me I the services I receive will t	and that I will have the op	portur	nity to ask questions.	,				
 I may refuse servil I acknowledge that I h Act (HIPAA). I can als receiving the vaccine. 	ave received a cop	by of the Oklahoma State D te agency website. I also ac	epartment of Health Priva knowledge that I received	acy Sta I the m	ntement as required by anufacturer-specific F	y the Hea act Sheet	Ith Informat for Recipie	tion Portaints and	ability and Ac Caregivers p	countability rior to

Client/Guardian Signature:

†Client must be aged 16 years or older to receive the vaccine.

Clinic:

Today's Date:

Date: ____

ODH 1401/12-17-2020

****FOR OSDH USE ONLY***

ient Name (Last, First, MI)	Client	Client DOB (MM/DD/YYYY)	
	OFFICE USE ONLY – DO NOT WRITE BELOW	OW	
Client completed the manufacturer's screening questions:	N		
/accine Manufacturer: .ot #:	Site: LT DELTOID IM RT DELTOID IM	EUA*/VIS given?	Dose Number:
exp. Date:	☐ LT VAST LAT IM☐ RT VAST LAT IM☐	Reaction?	1st
/accination Complete?	□Not administered □Partially administered □No recorded completion status	ed UNo recorded completion stat	tus
Provider Signature:			
AU = Emergency Use Agreement			
ogress Note:			
			4